Galya Blachman serves as the Chief Legal Officer and Head of Business Development at Enliven Therapeutics, a company developing small molecule kinase inhibitors to treat cancer. She is a part-time Legal Advisor to 5AM Ventures and on a pro bono basis, is the General counsel and serves on the board of directors of Biotech Connection Bay Area. Prior to Enliven, she was the General Counsel and Chief Compliance Officer at 5AM Ventures and was also the COO of the 4:59 Initiative – 5AM’s company creation engine. Prior to 5AM, Dr. Blachman was Legal Director at Stemcentrx, which was acquired by AbbVie in 2016 and where she remained to work in the Legal R&D transactions team. Dr. Blachman began her career practicing intellectual property law at Slaughter & May and Simmons & Simmons in the United Kingdom. She received her law degree in England from BPP University Law School and completed a postgraduate diploma in intellectual property law at Oxford University. She earned a Ph.D. in Pharmacology from Cambridge University, and an M.Sc. in Pharmacology and a B.Sc. (honors) in Biochemistry and Hebrew from the University of Cape Town, South Africa.